Longevity BS, Breakthroughs and What Comes Next

In Part Two of my conversation with Dr Steven Lu, Everlab’s co-founder and Chief Medical Officer, we unpack what’s actually worth measuring, which treatments show real promise, what’s still experimental and what the future of preventative healthcare could look like.

And why, when it comes to optimising our health, we should be problem-centric, not solution-centric.

We dive into:

What keeps Steven up at night as Everlab grows and expands internationally.What’s actually worth measuring: From Lp(a), a genetically influenced cardiovascular risk marker, to body composition, and the tests Steven believes deserve more attention.GLP-1s, breakthrough drugs or misunderstood medicine? Their potential, the risks of poor dosing and inadequate support, and why protecting muscle and bone health matters.The peptide boom: What’s backed by evidence, the safety and quality concerns, and why Steven isn’t ready to inject them himself. Yet.Being problem-centric, not solution-centric: Why chasing the latest tests, treatments and biohacks isn’t necessarily the best approach to better health.AI and the future of primary care: How Everlab’s Concierge is bringing AI into healthcare while keeping clinicians in the loop.The next frontier of preventative medicine: Pharmacogenetics, personalised care and emerging Alzheimer’s blood tests.Hype or worth it? Steven’s rapid-fire take on full-body MRIs, continuous glucose monitors, wearables, NAD+ infusions and creatine, plus the health habits he thinks are overhyped and underappreciated.

Chapters

00:00 Preview: what's real in longevity

01:12 What keeps Steven up at night: leading Everlab through uncharted waters

03:00 What's worth measuring: Lp(a) and body composition

05:28 GLP-1s: what works, and what goes wrong without support

12:13 Peptides: the evidence gap and his "would I take it myself?" test

18:28 Be problem-centric, not solution-centric

22:41 Pharmacogenetics, tailored care and the public system's role